Advertisement
Australia markets close in 5 hours 41 minutes
  • ALL ORDS

    7,965.60
    +27.70 (+0.35%)
     
  • ASX 200

    7,711.40
    +27.90 (+0.36%)
     
  • AUD/USD

    0.6494
    +0.0005 (+0.07%)
     
  • OIL

    83.43
    +0.07 (+0.08%)
     
  • GOLD

    2,335.90
    -6.20 (-0.26%)
     
  • Bitcoin AUD

    102,452.77
    -395.36 (-0.38%)
     
  • CMC Crypto 200

    1,432.85
    +18.09 (+1.28%)
     
  • AUD/EUR

    0.6061
    +0.0004 (+0.07%)
     
  • AUD/NZD

    1.0927
    -0.0003 (-0.03%)
     
  • NZX 50

    11,863.03
    +59.75 (+0.51%)
     
  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     
  • DAX

    18,137.65
    +276.85 (+1.55%)
     
  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     
  • NIKKEI 225

    38,100.34
    +548.18 (+1.46%)
     

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. While that's an impressive market beat, there was a point in early 2021 when Fulgent's stock was up over 1,300%. This wild stock movement was spurred on by incredible revenue growth due to Fulgent's ability to pivot to providing COVID-19 tests early in 2020.